| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director | Chief Strategy Officer +1 more
2 companies
Sushil Patel is Chief Executive Officer at REPL and has filed Form 4s across 2 companies. Sushil Patel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $18.8M at current prices.
Historically, Sushil Patel's trades have earned a middling insider score of 64/100 across 12 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +17.7%.
The biggest single holding is REPL (~$14.6M) as Chief Executive Officer. The REPL filings lean toward selling, a net 173,924 shares.
Sushil Patel has 25 Form 4 filings on record from May 2021 to August 2026, across 2 companies: Chief Executive Officer at Replimune Group (REPL), 2021–2026; Director at Revolution Medicines (RVMD), 2022–2026.
The 49 reported transactions were 22 open-market sales, 12 stock awards, 11 option or other derivative awards and 4 option exercises.
Counted by filing, the open-market trades come to no purchases and 13 sales worth about $3.3M.
The largest open-market sale was 5,580 shares of RVMD at an average $187.99 on June 29, 2026, about $1.0M.
7 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 5 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 39,341 | $12.97 | $510,252.77 | -5.3% | - | - | |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Director | Sale+OE10b5-1 | 5,580 | $187.99 | $1,048,967.30 | -20.5% | +4.7% | - | |
| May 18, 2026 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 37,324 | $5.08 | $189,605.92 | -4.8% | +192.0% | - | |
| Dec 2, 2025 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell10b5-1 | 10,000 | $11.13 | $111,300.00 | -2.9% | -28.4% | - | |
| May 20, 2025 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 25,105 | $8.06 | $202,346.30 | -6.8% | -42.0% | -43.9% | |
| Dec 16, 2024 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell10b5-1 | 10,000 | $12.42 | $124,200.00 | -4.7% | -5.6% | -23.0% | |
| Oct 31, 2024 | RVMD Revolution Medicines, Inc. | Director | Sale+OE10b5-1 | 5,000 | $54.14 | $270,714.50 | -20.0% | -23.5% | +10.0% | |
| Jul 9, 2024 | RVMD Revolution Medicines, Inc. | Director | Sale+OE10b5-1 | 2,155 | $44.00 | $94,820.00 | -9.7% | +7.8% | -12.3% | |
| May 16, 2024 | REPL Replimune Group, Inc. | Chief Executive Officer | Sell | 20,194 | $6.47 | $130,655.18 | -8.7% | +46.7% | +16.8% | |
| Apr 10, 2024 | RVMD Revolution Medicines, Inc. | Director | Sale+OE10b5-1 | 2,155 | $37.00 | $79,735.00 | -12.1% | +20.3% | -7.8% |